Shares of Cellectis SA (NASDAQ:CLLS) were down 2.6% on Monday . The stock traded as low as $24.31 and last traded at $24.39, with a volume of 53,236 shares trading hands. The stock had previously closed at $25.05.
Several analysts recently weighed in on CLLS shares. Jefferies Group reissued a “buy” rating on shares of Cellectis SA in a report on Friday, August 5th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $65.00 target price on shares of Cellectis SA in a research note on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $44.17.
The firm’s market capitalization is $861.72 million. The stock has a 50-day moving average of $26.75 and a 200 day moving average of $27.72.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/cellectis-sa-clls-stock-price-down-2-6.html
Several hedge funds and other institutional investors have recently made changes to their positions in CLLS. Apex Capital Management bought a new position in shares of Cellectis SA during the first quarter worth approximately $254,000. HighTower Advisors LLC raised its position in shares of Cellectis SA by 0.3% in the second quarter. HighTower Advisors LLC now owns 13,440 shares of the company’s stock worth $357,000 after buying an additional 40 shares in the last quarter. GAM Holding AG raised its position in shares of Cellectis SA by 61.7% in the second quarter. GAM Holding AG now owns 15,220 shares of the company’s stock worth $405,000 after buying an additional 5,810 shares in the last quarter. Fiera Capital Corp bought a new position in shares of Cellectis SA during the second quarter worth approximately $452,000. Finally, Picton Mahoney Asset Management raised its position in shares of Cellectis SA by 40.7% in the first quarter. Picton Mahoney Asset Management now owns 26,800 shares of the company’s stock worth $737,000 after buying an additional 7,750 shares in the last quarter.
Cellectis SA Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis SA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cellectis SA and related companies with MarketBeat.com’s FREE daily email newsletter.